Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma

Background Super-enhancers (SEs) play a crucial role in cancer, which is often associate with activated oncogenes. However, little is known about how SEs facilitate tumour suppression. Individuals with Down syndrome exhibit a remarkably reduced incidence of breast cancer (BC), moving the search for...

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer Vol. 19; no. 1; pp. 1 - 19
Main Authors Deng, Rong, Huang, Jun-Hao, Wang, Yan, Zhou, Li-Huan, Wang, Zi-Feng, Hu, Bing-Xin, Chen, Yu-Hong, Yang, Dong, Mai, Jia, Li, Zhi-Ling, Zhang, Hai-Liang, Huang, Yun, Peng, Xiao-Dan, Feng, Gong-Kan, Zhu, Xiao-Feng, Tang, Jun
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 08.08.2020
BioMed Central
BMC
Subjects
Analysis
BRD4
Breast cancer
Breast carcinoma
Calcineurin
Cancer genetics
Carcinoma
Chromosome 21
Cloning
CRISPR
Datasets
Down syndrome
Down's syndrome
Drug resistance
Enhancers
Epigenetics
Gene expression
Genes
Genome editing
Genomes
Genomics
Immunohistochemistry
Information management
Malignancy
Medical prognosis
Medical research
Metastases
Patients
Phenotypes
Plasmids
RCAN1.4
RUNX3
Runx3 protein
Super-enhancer
Survival analysis
Tumor suppressor genes
Tumors
Online AccessGet full text

Cover

Abstract Background Super-enhancers (SEs) play a crucial role in cancer, which is often associate with activated oncogenes. However, little is known about how SEs facilitate tumour suppression. Individuals with Down syndrome exhibit a remarkably reduced incidence of breast cancer (BC), moving the search for tumor suppressor genes on human chromosome 21 (HSA21). In this study, we aim to identify and explore potential mechanisms by which SEs are established for tumor suppressor RCAN1.4 on HSA21 in BC. Methods In silico analysis and immunohistochemical staining were used to assess the expression and clinical relevance of RCAN1.4 and RUNX3 in BC. Function experiments were performed to evaluate the effects of RCAN1.4 on the malignancy of breast carcinoma in vitro and in vivo. ChIP-seq data analysis, ChIP-qPCR, double-CRISPR genome editing, and luciferase reporter assay were utilized to confirm RUNX3 was involved in regulating RCAN1.4-associated SE in BC. The clinical value of co-expression of RCAN1.4 and RUNX3 was evaluated in BC patients. Results Here, we characterized RCAN1.4 as a potential tumour suppressor in BC. RCAN1.4 loss promoted tumour metastasis to bone and brain, and its overexpression inhibited tumour growth by blocking the calcineurin-NFATc1 pathway. Unexpectedly, we found RCAN1.4 expression was driven by a ~ 23 kb-long SE. RCAN1.4-SE.sup.distal was sensitive to BRD4 inhibition, and its deletion decreased RCAN1.4 expression by over 90% and induced the malignant phenotype of BC cells. We also discovered that the binding sites in the SE region of RCAN1.4 were enriched for consensus sequences of transcription factor RUNX3. Knockdown of RUNX3 repressed the luciferase activity and also decreased H3K27ac enrichment binding at the SE region of RCAN1.4. Furthermore, abnormal SE-driven RCAN1.4 expression mediated by RUNX3 loss could be physiologically significant and clinically relevant in BC patients. Notably, we established a prognostic model based on RCAN1.4 and RUNX3 co-expression that effectively predicted the overall survival in BC patients. Conclusions These findings reveal an important role of SEs in facilitating tumour suppression in BC. Considering that the combination of low RCAN1.4 and low RUNX3 expression has worse prognosis, RUNX3-RCAN1.4 axis maybe a novel prognostic biomarker and therapeutic target for BC patients. Keywords: Super-enhancer, RCAN1.4, RUNX3, BRD4, Breast carcinoma, Malignancy, Tumor suppressor
AbstractList Super-enhancers (SEs) play a crucial role in cancer, which is often associate with activated oncogenes. However, little is known about how SEs facilitate tumour suppression. Individuals with Down syndrome exhibit a remarkably reduced incidence of breast cancer (BC), moving the search for tumor suppressor genes on human chromosome 21 (HSA21). In this study, we aim to identify and explore potential mechanisms by which SEs are established for tumor suppressor RCAN1.4 on HSA21 in BC. In silico analysis and immunohistochemical staining were used to assess the expression and clinical relevance of RCAN1.4 and RUNX3 in BC. Function experiments were performed to evaluate the effects of RCAN1.4 on the malignancy of breast carcinoma in vitro and in vivo. ChIP-seq data analysis, ChIP-qPCR, double-CRISPR genome editing, and luciferase reporter assay were utilized to confirm RUNX3 was involved in regulating RCAN1.4-associated SE in BC. The clinical value of co-expression of RCAN1.4 and RUNX3 was evaluated in BC patients. Here, we characterized RCAN1.4 as a potential tumour suppressor in BC. RCAN1.4 loss promoted tumour metastasis to bone and brain, and its overexpression inhibited tumour growth by blocking the calcineurin-NFATc1 pathway. Unexpectedly, we found RCAN1.4 expression was driven by a ~ 23 kb-long SE. RCAN1.4-SE.sup.distal was sensitive to BRD4 inhibition, and its deletion decreased RCAN1.4 expression by over 90% and induced the malignant phenotype of BC cells. We also discovered that the binding sites in the SE region of RCAN1.4 were enriched for consensus sequences of transcription factor RUNX3. Knockdown of RUNX3 repressed the luciferase activity and also decreased H3K27ac enrichment binding at the SE region of RCAN1.4. Furthermore, abnormal SE-driven RCAN1.4 expression mediated by RUNX3 loss could be physiologically significant and clinically relevant in BC patients. Notably, we established a prognostic model based on RCAN1.4 and RUNX3 co-expression that effectively predicted the overall survival in BC patients. These findings reveal an important role of SEs in facilitating tumour suppression in BC. Considering that the combination of low RCAN1.4 and low RUNX3 expression has worse prognosis, RUNX3-RCAN1.4 axis maybe a novel prognostic biomarker and therapeutic target for BC patients.
Background Super-enhancers (SEs) play a crucial role in cancer, which is often associate with activated oncogenes. However, little is known about how SEs facilitate tumour suppression. Individuals with Down syndrome exhibit a remarkably reduced incidence of breast cancer (BC), moving the search for tumor suppressor genes on human chromosome 21 (HSA21). In this study, we aim to identify and explore potential mechanisms by which SEs are established for tumor suppressor RCAN1.4 on HSA21 in BC. Methods In silico analysis and immunohistochemical staining were used to assess the expression and clinical relevance of RCAN1.4 and RUNX3 in BC. Function experiments were performed to evaluate the effects of RCAN1.4 on the malignancy of breast carcinoma in vitro and in vivo. ChIP-seq data analysis, ChIP-qPCR, double-CRISPR genome editing, and luciferase reporter assay were utilized to confirm RUNX3 was involved in regulating RCAN1.4-associated SE in BC. The clinical value of co-expression of RCAN1.4 and RUNX3 was evaluated in BC patients. Results Here, we characterized RCAN1.4 as a potential tumour suppressor in BC. RCAN1.4 loss promoted tumour metastasis to bone and brain, and its overexpression inhibited tumour growth by blocking the calcineurin-NFATc1 pathway. Unexpectedly, we found RCAN1.4 expression was driven by a ~ 23 kb-long SE. RCAN1.4-SEdistal was sensitive to BRD4 inhibition, and its deletion decreased RCAN1.4 expression by over 90% and induced the malignant phenotype of BC cells. We also discovered that the binding sites in the SE region of RCAN1.4 were enriched for consensus sequences of transcription factor RUNX3. Knockdown of RUNX3 repressed the luciferase activity and also decreased H3K27ac enrichment binding at the SE region of RCAN1.4. Furthermore, abnormal SE-driven RCAN1.4 expression mediated by RUNX3 loss could be physiologically significant and clinically relevant in BC patients. Notably, we established a prognostic model based on RCAN1.4 and RUNX3 co-expression that effectively predicted the overall survival in BC patients. Conclusions These findings reveal an important role of SEs in facilitating tumour suppression in BC. Considering that the combination of low RCAN1.4 and low RUNX3 expression has worse prognosis, RUNX3-RCAN1.4 axis maybe a novel prognostic biomarker and therapeutic target for BC patients.
Abstract Background Super-enhancers (SEs) play a crucial role in cancer, which is often associate with activated oncogenes. However, little is known about how SEs facilitate tumour suppression. Individuals with Down syndrome exhibit a remarkably reduced incidence of breast cancer (BC), moving the search for tumor suppressor genes on human chromosome 21 (HSA21). In this study, we aim to identify and explore potential mechanisms by which SEs are established for tumor suppressor RCAN1.4 on HSA21 in BC. Methods In silico analysis and immunohistochemical staining were used to assess the expression and clinical relevance of RCAN1.4 and RUNX3 in BC. Function experiments were performed to evaluate the effects of RCAN1.4 on the malignancy of breast carcinoma in vitro and in vivo. ChIP-seq data analysis, ChIP-qPCR, double-CRISPR genome editing, and luciferase reporter assay were utilized to confirm RUNX3 was involved in regulating RCAN1.4-associated SE in BC. The clinical value of co-expression of RCAN1.4 and RUNX3 was evaluated in BC patients. Results Here, we characterized RCAN1.4 as a potential tumour suppressor in BC. RCAN1.4 loss promoted tumour metastasis to bone and brain, and its overexpression inhibited tumour growth by blocking the calcineurin-NFATc1 pathway. Unexpectedly, we found RCAN1.4 expression was driven by a ~ 23 kb-long SE. RCAN1.4-SEdistal was sensitive to BRD4 inhibition, and its deletion decreased RCAN1.4 expression by over 90% and induced the malignant phenotype of BC cells. We also discovered that the binding sites in the SE region of RCAN1.4 were enriched for consensus sequences of transcription factor RUNX3. Knockdown of RUNX3 repressed the luciferase activity and also decreased H3K27ac enrichment binding at the SE region of RCAN1.4. Furthermore, abnormal SE-driven RCAN1.4 expression mediated by RUNX3 loss could be physiologically significant and clinically relevant in BC patients. Notably, we established a prognostic model based on RCAN1.4 and RUNX3 co-expression that effectively predicted the overall survival in BC patients. Conclusions These findings reveal an important role of SEs in facilitating tumour suppression in BC. Considering that the combination of low RCAN1.4 and low RUNX3 expression has worse prognosis, RUNX3-RCAN1.4 axis maybe a novel prognostic biomarker and therapeutic target for BC patients.
Background Super-enhancers (SEs) play a crucial role in cancer, which is often associate with activated oncogenes. However, little is known about how SEs facilitate tumour suppression. Individuals with Down syndrome exhibit a remarkably reduced incidence of breast cancer (BC), moving the search for tumor suppressor genes on human chromosome 21 (HSA21). In this study, we aim to identify and explore potential mechanisms by which SEs are established for tumor suppressor RCAN1.4 on HSA21 in BC. Methods In silico analysis and immunohistochemical staining were used to assess the expression and clinical relevance of RCAN1.4 and RUNX3 in BC. Function experiments were performed to evaluate the effects of RCAN1.4 on the malignancy of breast carcinoma in vitro and in vivo. ChIP-seq data analysis, ChIP-qPCR, double-CRISPR genome editing, and luciferase reporter assay were utilized to confirm RUNX3 was involved in regulating RCAN1.4-associated SE in BC. The clinical value of co-expression of RCAN1.4 and RUNX3 was evaluated in BC patients. Results Here, we characterized RCAN1.4 as a potential tumour suppressor in BC. RCAN1.4 loss promoted tumour metastasis to bone and brain, and its overexpression inhibited tumour growth by blocking the calcineurin-NFATc1 pathway. Unexpectedly, we found RCAN1.4 expression was driven by a ~ 23 kb-long SE. RCAN1.4-SE.sup.distal was sensitive to BRD4 inhibition, and its deletion decreased RCAN1.4 expression by over 90% and induced the malignant phenotype of BC cells. We also discovered that the binding sites in the SE region of RCAN1.4 were enriched for consensus sequences of transcription factor RUNX3. Knockdown of RUNX3 repressed the luciferase activity and also decreased H3K27ac enrichment binding at the SE region of RCAN1.4. Furthermore, abnormal SE-driven RCAN1.4 expression mediated by RUNX3 loss could be physiologically significant and clinically relevant in BC patients. Notably, we established a prognostic model based on RCAN1.4 and RUNX3 co-expression that effectively predicted the overall survival in BC patients. Conclusions These findings reveal an important role of SEs in facilitating tumour suppression in BC. Considering that the combination of low RCAN1.4 and low RUNX3 expression has worse prognosis, RUNX3-RCAN1.4 axis maybe a novel prognostic biomarker and therapeutic target for BC patients. Keywords: Super-enhancer, RCAN1.4, RUNX3, BRD4, Breast carcinoma, Malignancy, Tumor suppressor
Super-enhancers (SEs) play a crucial role in cancer, which is often associate with activated oncogenes. However, little is known about how SEs facilitate tumour suppression. Individuals with Down syndrome exhibit a remarkably reduced incidence of breast cancer (BC), moving the search for tumor suppressor genes on human chromosome 21 (HSA21). In this study, we aim to identify and explore potential mechanisms by which SEs are established for tumor suppressor RCAN1.4 on HSA21 in BC.BACKGROUNDSuper-enhancers (SEs) play a crucial role in cancer, which is often associate with activated oncogenes. However, little is known about how SEs facilitate tumour suppression. Individuals with Down syndrome exhibit a remarkably reduced incidence of breast cancer (BC), moving the search for tumor suppressor genes on human chromosome 21 (HSA21). In this study, we aim to identify and explore potential mechanisms by which SEs are established for tumor suppressor RCAN1.4 on HSA21 in BC.In silico analysis and immunohistochemical staining were used to assess the expression and clinical relevance of RCAN1.4 and RUNX3 in BC. Function experiments were performed to evaluate the effects of RCAN1.4 on the malignancy of breast carcinoma in vitro and in vivo. ChIP-seq data analysis, ChIP-qPCR, double-CRISPR genome editing, and luciferase reporter assay were utilized to confirm RUNX3 was involved in regulating RCAN1.4-associated SE in BC. The clinical value of co-expression of RCAN1.4 and RUNX3 was evaluated in BC patients.METHODSIn silico analysis and immunohistochemical staining were used to assess the expression and clinical relevance of RCAN1.4 and RUNX3 in BC. Function experiments were performed to evaluate the effects of RCAN1.4 on the malignancy of breast carcinoma in vitro and in vivo. ChIP-seq data analysis, ChIP-qPCR, double-CRISPR genome editing, and luciferase reporter assay were utilized to confirm RUNX3 was involved in regulating RCAN1.4-associated SE in BC. The clinical value of co-expression of RCAN1.4 and RUNX3 was evaluated in BC patients.Here, we characterized RCAN1.4 as a potential tumour suppressor in BC. RCAN1.4 loss promoted tumour metastasis to bone and brain, and its overexpression inhibited tumour growth by blocking the calcineurin-NFATc1 pathway. Unexpectedly, we found RCAN1.4 expression was driven by a ~ 23 kb-long SE. RCAN1.4-SEdistal was sensitive to BRD4 inhibition, and its deletion decreased RCAN1.4 expression by over 90% and induced the malignant phenotype of BC cells. We also discovered that the binding sites in the SE region of RCAN1.4 were enriched for consensus sequences of transcription factor RUNX3. Knockdown of RUNX3 repressed the luciferase activity and also decreased H3K27ac enrichment binding at the SE region of RCAN1.4. Furthermore, abnormal SE-driven RCAN1.4 expression mediated by RUNX3 loss could be physiologically significant and clinically relevant in BC patients. Notably, we established a prognostic model based on RCAN1.4 and RUNX3 co-expression that effectively predicted the overall survival in BC patients.RESULTSHere, we characterized RCAN1.4 as a potential tumour suppressor in BC. RCAN1.4 loss promoted tumour metastasis to bone and brain, and its overexpression inhibited tumour growth by blocking the calcineurin-NFATc1 pathway. Unexpectedly, we found RCAN1.4 expression was driven by a ~ 23 kb-long SE. RCAN1.4-SEdistal was sensitive to BRD4 inhibition, and its deletion decreased RCAN1.4 expression by over 90% and induced the malignant phenotype of BC cells. We also discovered that the binding sites in the SE region of RCAN1.4 were enriched for consensus sequences of transcription factor RUNX3. Knockdown of RUNX3 repressed the luciferase activity and also decreased H3K27ac enrichment binding at the SE region of RCAN1.4. Furthermore, abnormal SE-driven RCAN1.4 expression mediated by RUNX3 loss could be physiologically significant and clinically relevant in BC patients. Notably, we established a prognostic model based on RCAN1.4 and RUNX3 co-expression that effectively predicted the overall survival in BC patients.These findings reveal an important role of SEs in facilitating tumour suppression in BC. Considering that the combination of low RCAN1.4 and low RUNX3 expression has worse prognosis, RUNX3-RCAN1.4 axis maybe a novel prognostic biomarker and therapeutic target for BC patients.CONCLUSIONSThese findings reveal an important role of SEs in facilitating tumour suppression in BC. Considering that the combination of low RCAN1.4 and low RUNX3 expression has worse prognosis, RUNX3-RCAN1.4 axis maybe a novel prognostic biomarker and therapeutic target for BC patients.
ArticleNumber 122
Audience Academic
Author Deng, Rong
Zhang, Hai-Liang
Feng, Gong-Kan
Zhou, Li-Huan
Mai, Jia
Hu, Bing-Xin
Yang, Dong
Li, Zhi-Ling
Huang, Jun-Hao
Wang, Yan
Zhu, Xiao-Feng
Peng, Xiao-Dan
Wang, Zi-Feng
Chen, Yu-Hong
Tang, Jun
Huang, Yun
Author_xml – sequence: 1
  givenname: Rong
  surname: Deng
  fullname: Deng, Rong
– sequence: 2
  givenname: Jun-Hao
  surname: Huang
  fullname: Huang, Jun-Hao
– sequence: 3
  givenname: Yan
  surname: Wang
  fullname: Wang, Yan
– sequence: 4
  givenname: Li-Huan
  surname: Zhou
  fullname: Zhou, Li-Huan
– sequence: 5
  givenname: Zi-Feng
  surname: Wang
  fullname: Wang, Zi-Feng
– sequence: 6
  givenname: Bing-Xin
  surname: Hu
  fullname: Hu, Bing-Xin
– sequence: 7
  givenname: Yu-Hong
  surname: Chen
  fullname: Chen, Yu-Hong
– sequence: 8
  givenname: Dong
  surname: Yang
  fullname: Yang, Dong
– sequence: 9
  givenname: Jia
  surname: Mai
  fullname: Mai, Jia
– sequence: 10
  givenname: Zhi-Ling
  surname: Li
  fullname: Li, Zhi-Ling
– sequence: 11
  givenname: Hai-Liang
  surname: Zhang
  fullname: Zhang, Hai-Liang
– sequence: 12
  givenname: Yun
  surname: Huang
  fullname: Huang, Yun
– sequence: 13
  givenname: Xiao-Dan
  surname: Peng
  fullname: Peng, Xiao-Dan
– sequence: 14
  givenname: Gong-Kan
  surname: Feng
  fullname: Feng, Gong-Kan
– sequence: 15
  givenname: Xiao-Feng
  surname: Zhu
  fullname: Zhu, Xiao-Feng
– sequence: 16
  givenname: Jun
  orcidid: 0000-0002-9788-8389
  surname: Tang
  fullname: Tang, Jun
BookMark eNp9kktv1DAUhSNURB_wB1hFYsMmg1-xkw3SaEpLpQokBGvLY9_MeJTYwXaqtr8eZ6YIpkIoUXx1fc7n5OacFyfOOyiKtxgtMG74h4hJy2iFCKoQJpRXjy-KM8wEr1jdNid_1afFeYw7hLBoBHtVnFIiBEaEnhX3lzaGaUzWu9J3ZZxGCBW4rXI6FybYO3BlmgYf5r0xQIy53ICD8ttq-QUvWAn3-_ZMGIMffIJYpi2Ug-rtxmXQw0xeB1AxlVoFbZ0f1OviZaf6CG-e1ovix9Wn76vP1e3X65vV8rbSNUOpIogy0Kpl2DRtfutGt21tcsMIoLypMdECeEe5qRXltamxQarRaK04Bqw5vShuDlzj1U6OwQ4qPEivrNw3fNhIFZLVPUgtGqp1g8G0iK2Nzk9hujxk0mLOO5xZHw-scVoPYDS4FFR_BD3ecXYrN_5OCpZ_BSUZ8P4JEPzPCWKSg40a-l458FOUhNF8Y9qKLH33TLrzU3B5VLOqphhxwf-oNip_gHWdz-fqGSqXnFIkOGLzsYt_qPJlYLA6h6qzuX9kaA4GHXyMATqpbVJzSLLR9hIjOSdQHhIocwLlPoHyMVvJM-vv8fzH9As9P98z
CitedBy_id crossref_primary_10_1038_s41420_023_01775_6
crossref_primary_10_1172_jci_insight_177032
crossref_primary_10_1523_JNEUROSCI_1006_23_2023
crossref_primary_10_1080_15548627_2020_1850609
crossref_primary_10_1177_11779322231162767
crossref_primary_10_1186_s13046_022_02416_z
crossref_primary_10_1134_S0026893322030116
crossref_primary_10_1210_endocr_bqae111
crossref_primary_10_2217_epi_2023_0409
crossref_primary_10_1038_s41467_021_22618_x
crossref_primary_10_1158_2643_3230_BCD_23_0211
crossref_primary_10_1038_s41419_023_05892_z
crossref_primary_10_1186_s12943_023_01767_1
crossref_primary_10_1002_advs_202403592
crossref_primary_10_3389_fmolb_2021_662331
crossref_primary_10_1186_s12957_024_03441_2
crossref_primary_10_1093_carcin_bgac049
crossref_primary_10_3390_ijms23020764
crossref_primary_10_1016_j_ijbiomac_2025_140501
crossref_primary_10_1089_thy_2022_0687
crossref_primary_10_1186_s12943_024_02033_8
crossref_primary_10_1016_j_canlet_2024_217284
crossref_primary_10_1016_j_semcancer_2022_04_005
crossref_primary_10_12688_f1000research_148778_1
crossref_primary_10_1093_jpp_rgae063
crossref_primary_10_3389_fimmu_2025_1517519
crossref_primary_10_3390_genes14040800
crossref_primary_10_1038_s41419_023_05966_y
crossref_primary_10_1186_s13046_023_02763_5
crossref_primary_10_1016_j_bcp_2021_114806
crossref_primary_10_1016_j_jtho_2022_08_002
crossref_primary_10_3389_fgene_2021_762529
crossref_primary_10_1038_s41598_021_86097_2
crossref_primary_10_1186_s12885_024_12807_4
crossref_primary_10_1038_s41419_021_03538_6
crossref_primary_10_1016_j_canlet_2024_216811
crossref_primary_10_3390_ijms24031964
crossref_primary_10_37349_etat_2022_00094
crossref_primary_10_1088_1758_5090_ad82e0
crossref_primary_10_1038_s41420_023_01574_z
crossref_primary_10_1038_s41388_020_01602_7
crossref_primary_10_3390_cancers15020466
crossref_primary_10_1038_s41389_022_00436_0
crossref_primary_10_1186_s10020_022_00492_7
crossref_primary_10_1186_s12967_025_06098_x
crossref_primary_10_3389_fgene_2023_1258862
crossref_primary_10_1097_MD_0000000000040601
crossref_primary_10_3390_ijms25063103
Cites_doi 10.1038/gim.2016.23
10.3390/biomedicines6010016
10.1038/nature11412
10.1086/520000
10.1007/s10549-009-0674-9
10.1038/nrg3207
10.1186/s12943-020-01181-x
10.1016/j.canlet.2019.11.027
10.1038/onc.2010.467
10.1073/pnas.1705236114
10.1038/nature08062
10.1002/jcb.24074
10.1016/j.molcel.2015.02.014
10.2217/fon.09.88
10.1016/j.cell.2013.03.036
10.1074/jbc.M600184200
10.1016/j.ccell.2019.06.002
10.1186/s12943-020-01195-5
10.1074/jbc.M506205200
10.1038/s41698-020-0108-z
10.1038/ng.3771
10.1038/nature14904
10.1016/j.molcel.2018.04.028
10.1016/j.cell.2015.08.063
10.1126/scitranslmed.aal1645
10.1074/jbc.M900639200
10.1016/j.cell.2014.11.021
10.1371/journal.pone.0114485
10.1038/ncomms10044
10.1038/s41598-017-02257-3
10.1080/13543776.2020.1702645
10.1053/j.gastro.2017.05.045
10.1016/j.cell.2013.09.053
10.1016/j.gendis.2018.05.001
10.1159/000134173
10.1038/nature16508
10.1038/sj.onc.1210861
10.3322/caac.21492
10.1016/j.cell.2013.03.035
10.1186/s12943-018-0931-9
10.1186/s12943-019-1024-0
10.1369/0022155418797315
10.3389/fphar.2019.00361
10.1038/ncomms14802
10.1158/1541-7786.MCR-06-0126
ContentType Journal Article
Copyright COPYRIGHT 2020 BioMed Central Ltd.
2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2020
Copyright_xml – notice: COPYRIGHT 2020 BioMed Central Ltd.
– notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2020
DBID AAYXX
CITATION
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12943-020-01236-z
DatabaseName CrossRef
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-4598
EndPage 19
ExternalDocumentID oai_doaj_org_article_c783cc81ed904bdc9047df12929166f1
PMC7414732
A633076042
10_1186_s12943_020_01236_z
GrantInformation_xml – fundername: ;
  grantid: 201707010086
– fundername: ;
  grantid: 81972481; 81772835; 81972855
– fundername: ;
  grantid: 81772624; 81630079
– fundername: ;
  grantid: 2019A1515011209; 2017A030313481
– fundername: ;
  grantid: 201803010007
GroupedDBID ---
0R~
123
29M
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PZZ
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
PMFND
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c540t-2034eca941d892778c995dca9d7e368512c7e6f36d5a365d51d0a8c0ba61e1c63
IEDL.DBID M48
ISSN 1476-4598
IngestDate Wed Aug 27 01:33:11 EDT 2025
Thu Aug 21 14:36:17 EDT 2025
Fri Jul 11 02:43:05 EDT 2025
Sat Jul 26 02:22:31 EDT 2025
Tue Jun 17 21:46:10 EDT 2025
Tue Jun 10 20:19:38 EDT 2025
Thu Apr 24 23:09:06 EDT 2025
Tue Jul 01 01:01:18 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-2034eca941d892778c995dca9d7e368512c7e6f36d5a365d51d0a8c0ba61e1c63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-9788-8389
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12943-020-01236-z
PMID 32771023
PQID 2435310676
PQPubID 42702
PageCount 19
ParticipantIDs doaj_primary_oai_doaj_org_article_c783cc81ed904bdc9047df12929166f1
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7414732
proquest_miscellaneous_2432431397
proquest_journals_2435310676
gale_infotracmisc_A633076042
gale_infotracacademiconefile_A633076042
crossref_citationtrail_10_1186_s12943_020_01236_z
crossref_primary_10_1186_s12943_020_01236_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-08-08
PublicationDateYYYYMMDD 2020-08-08
PublicationDate_xml – month: 08
  year: 2020
  text: 2020-08-08
  day: 08
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Molecular cancer
PublicationYear 2020
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References LF Chen (1236_CR37) 2012; 113
D Glodzik (1236_CR10) 2017; 49
B Gyorffy (1236_CR19) 2010; 123
E Cano (1236_CR20) 2005; 280
Y Wang (1236_CR9) 2015; 163
X Li (1236_CR30) 2019; 18
HE Pelish (1236_CR40) 2015; 526
E Ait Yahya-Graison (1236_CR15) 2007; 81
KH Baek (1236_CR31) 2009; 459
X Yin (1236_CR42) 2008; 27
F Crudele (1236_CR3) 2020; 19
P Sin-Chan (1236_CR45) 2019; 36
D Hnisz (1236_CR4) 2013; 155
H Hasle (1236_CR13) 2016; 18
L Qin (1236_CR32) 2006; 4
F Tang (1236_CR33) 2020; 4
WA Whyte (1236_CR7) 2013; 153
G Ermak (1236_CR18) 2009; 284
S Ryeom (1236_CR14) 2009; 5
R Deng (1236_CR17) 2011; 30
H Dong (1236_CR5) 2019; 18
D Hnisz (1236_CR8) 2015; 58
F Cao (1236_CR41) 2017; 7
H Liu (1236_CR38) 2018; 66
Y Li (1236_CR6) 2014; 9
F Spitz (1236_CR28) 2012; 13
CB Sun (1236_CR35) 2016; 38
SS Rao (1236_CR24) 2014; 159
SS Dhar (1236_CR39) 2018; 70
L Ke (1236_CR27) 2017; 114
T Lu (1236_CR46) 2020; 30
Y He (1236_CR34) 2019; 10
W Zhang (1236_CR43) 2020; 469
Cancer Genome Atlas N (1236_CR16) 2012; 490
H Jin (1236_CR21) 2017; 153
PA Betancur (1236_CR11) 2017; 8
VT Nguyen (1236_CR12) 2015; 6
JJ Qin (1236_CR23) 1846; 2014
F Bray (1236_CR1) 2018; 68
GK Yiu (1236_CR22) 2006; 281
A Weith (1236_CR29) 1996; 72
Y Feng (1236_CR2) 2018; 5
1236_CR44
1236_CR25
S Shu (1236_CR47) 2016; 529
J Loven (1236_CR26) 2013; 153
Y Tan (1236_CR36) 2020; 19
References_xml – volume: 18
  start-page: 1151
  year: 2016
  ident: 1236_CR13
  publication-title: Genet Med
  doi: 10.1038/gim.2016.23
– ident: 1236_CR25
  doi: 10.3390/biomedicines6010016
– volume: 490
  start-page: 61
  year: 2012
  ident: 1236_CR16
  publication-title: Nature
  doi: 10.1038/nature11412
– volume: 81
  start-page: 475
  year: 2007
  ident: 1236_CR15
  publication-title: Am J Hum Genet
  doi: 10.1086/520000
– volume: 123
  start-page: 725
  year: 2010
  ident: 1236_CR19
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-009-0674-9
– volume: 13
  start-page: 613
  year: 2012
  ident: 1236_CR28
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg3207
– volume: 19
  start-page: 61
  year: 2020
  ident: 1236_CR3
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01181-x
– volume: 469
  start-page: 510
  year: 2020
  ident: 1236_CR43
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2019.11.027
– volume: 30
  start-page: 944
  year: 2011
  ident: 1236_CR17
  publication-title: Oncogene
  doi: 10.1038/onc.2010.467
– volume: 114
  start-page: 9683
  year: 2017
  ident: 1236_CR27
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1705236114
– volume: 459
  start-page: 1126
  year: 2009
  ident: 1236_CR31
  publication-title: Nature
  doi: 10.1038/nature08062
– volume: 113
  start-page: 1470
  year: 2012
  ident: 1236_CR37
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.24074
– volume: 58
  start-page: 362
  year: 2015
  ident: 1236_CR8
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2015.02.014
– volume: 5
  start-page: 1185
  year: 2009
  ident: 1236_CR14
  publication-title: Future Oncol
  doi: 10.2217/fon.09.88
– volume: 153
  start-page: 320
  year: 2013
  ident: 1236_CR26
  publication-title: Cell
  doi: 10.1016/j.cell.2013.03.036
– volume: 281
  start-page: 12210
  year: 2006
  ident: 1236_CR22
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M600184200
– volume: 36
  start-page: 51
  year: 2019
  ident: 1236_CR45
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.06.002
– volume: 19
  start-page: 74
  year: 2020
  ident: 1236_CR36
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01195-5
– volume: 280
  start-page: 29435
  year: 2005
  ident: 1236_CR20
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M506205200
– volume: 2014
  start-page: 297
  year: 1846
  ident: 1236_CR23
  publication-title: Biochim Biophys Acta
– volume: 4
  start-page: 2
  year: 2020
  ident: 1236_CR33
  publication-title: NPJ Precis Oncol
  doi: 10.1038/s41698-020-0108-z
– volume: 49
  start-page: 341
  year: 2017
  ident: 1236_CR10
  publication-title: Nat Genet
  doi: 10.1038/ng.3771
– volume: 526
  start-page: 273
  year: 2015
  ident: 1236_CR40
  publication-title: Nature
  doi: 10.1038/nature14904
– volume: 70
  start-page: 825
  year: 2018
  ident: 1236_CR39
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2018.04.028
– volume: 163
  start-page: 174
  year: 2015
  ident: 1236_CR9
  publication-title: Cell
  doi: 10.1016/j.cell.2015.08.063
– ident: 1236_CR44
  doi: 10.1126/scitranslmed.aal1645
– volume: 284
  start-page: 11845
  year: 2009
  ident: 1236_CR18
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M900639200
– volume: 38
  start-page: 1056
  year: 2016
  ident: 1236_CR35
  publication-title: Yi Chuan
– volume: 159
  start-page: 1665
  year: 2014
  ident: 1236_CR24
  publication-title: Cell
  doi: 10.1016/j.cell.2014.11.021
– volume: 9
  start-page: e114485
  year: 2014
  ident: 1236_CR6
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0114485
– volume: 6
  start-page: 10044
  year: 2015
  ident: 1236_CR12
  publication-title: Nat Commun
  doi: 10.1038/ncomms10044
– volume: 7
  start-page: 2186
  year: 2017
  ident: 1236_CR41
  publication-title: Sci Rep
  doi: 10.1038/s41598-017-02257-3
– volume: 30
  start-page: 57
  year: 2020
  ident: 1236_CR46
  publication-title: Expert Opin Ther Pat
  doi: 10.1080/13543776.2020.1702645
– volume: 153
  start-page: 799
  year: 2017
  ident: 1236_CR21
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2017.05.045
– volume: 155
  start-page: 934
  year: 2013
  ident: 1236_CR4
  publication-title: Cell
  doi: 10.1016/j.cell.2013.09.053
– volume: 5
  start-page: 77
  year: 2018
  ident: 1236_CR2
  publication-title: Genes Dis
  doi: 10.1016/j.gendis.2018.05.001
– volume: 72
  start-page: 114
  year: 1996
  ident: 1236_CR29
  publication-title: Cytogenet Cell Genet
  doi: 10.1159/000134173
– volume: 529
  start-page: 413
  year: 2016
  ident: 1236_CR47
  publication-title: Nature
  doi: 10.1038/nature16508
– volume: 27
  start-page: 2118
  year: 2008
  ident: 1236_CR42
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210861
– volume: 68
  start-page: 394
  year: 2018
  ident: 1236_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21492
– volume: 153
  start-page: 307
  year: 2013
  ident: 1236_CR7
  publication-title: Cell
  doi: 10.1016/j.cell.2013.03.035
– volume: 18
  start-page: 3
  year: 2019
  ident: 1236_CR5
  publication-title: Mol Cancer
  doi: 10.1186/s12943-018-0931-9
– volume: 18
  start-page: 99
  year: 2019
  ident: 1236_CR30
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1024-0
– volume: 66
  start-page: 709
  year: 2018
  ident: 1236_CR38
  publication-title: J Histochem Cytochem
  doi: 10.1369/0022155418797315
– volume: 10
  start-page: 361
  year: 2019
  ident: 1236_CR34
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2019.00361
– volume: 8
  start-page: 14802
  year: 2017
  ident: 1236_CR11
  publication-title: Nat Commun
  doi: 10.1038/ncomms14802
– volume: 4
  start-page: 811
  year: 2006
  ident: 1236_CR32
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-06-0126
SSID ssj0017874
Score 2.485739
Snippet Background Super-enhancers (SEs) play a crucial role in cancer, which is often associate with activated oncogenes. However, little is known about how SEs...
Super-enhancers (SEs) play a crucial role in cancer, which is often associate with activated oncogenes. However, little is known about how SEs facilitate...
Abstract Background Super-enhancers (SEs) play a crucial role in cancer, which is often associate with activated oncogenes. However, little is known about how...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Analysis
BRD4
Breast cancer
Breast carcinoma
Calcineurin
Cancer genetics
Carcinoma
Chromosome 21
Cloning
CRISPR
Datasets
Down syndrome
Down's syndrome
Drug resistance
Enhancers
Epigenetics
Gene expression
Genes
Genome editing
Genomes
Genomics
Immunohistochemistry
Information management
Malignancy
Medical prognosis
Medical research
Metastases
Patients
Phenotypes
Plasmids
RCAN1.4
RUNX3
Runx3 protein
Super-enhancer
Survival analysis
Tumor suppressor genes
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9RAFB6koPgiWhWjVUYQfJDYnUvm8rhWSxHaB7HQtyGZmbUFN1lygba_3nMm2aVR0BchLCFzsiRzLvMd5uQ7hLyTMljpPc95aXkuK8hZKyNtroMuIDRUsUgkSadn6uRcfr0oLu60-sKasJEeeJy4Q6-N8N6wGOxCVsHDrw4rWKU4ABu1SokPrHnbZGraPwAzlNtPZIw67EBe4n4lFmFxofLb2TKU2Pr_jMm_10neWXiOH5NHE2Kky_FJn5B7sd4n98cekjf75MHptDv-lFx_vuraIcUA2qxoN2xim8f6EhXb5qHFwEb7Yd20OJYqYOEULCjSb0fLM_ZR0ng9FcbWdJMK9WJHASLSNcD1H8jNcYP_XGEle0899iGqm3X5jJwff_l-dJJPnRVyDwitB9cQMvrSShaM5Vobb20R4ELQERnpGfc6qpVQoSiFKkLBwqI0flGVikXmlXhO9uqmji8ItRpyrtJUzAC4UZaVduUrXQoDalaBhYyw7UQ7P9GOY_eLny6lH0a5UTkOlOOSctxtRj7s7tmMpBt_lf6E-ttJImF2ugBm5CYzcv8yo4y8R-07dGt4PF9OXyfASyJBllsqIXATU_KMHMwkwR39fHhrP24KB53jAEoFkvWpjLzdDeOdWOJWx2ZIMnAgIM-Intnd7M3mI_XVZaIEB1woteAv_8dUvCIPefIUpC4_IHt9O8TXgLz66k1ysl9ZqStC
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFA86UXwRnYrVKREEH6Ru-Wg-nuQ6HUPYHsTBfQttkrsNvO21vRe2_fWek5t7tQqDUkqTtE3PR35pTn-HkHdSBiu95yWvLS9lA3PWxkhb6qArcA1NrBJJ0smpOj6T36bVNH9wG3JY5cYnJkcdOo_fyPc5jOsC-c7Up8WvErNG4epqTqFxl9xD6jLUaj3dTrgYKKPc_Chj1P4AY5vEVUsMxeJClTejwShx9v_vmf-Nlvxr-Dl6TB5l3Egna0E_IXdiu0vurzNJXu-SByd5jfwpufpyOfSr5AloN6PDahH7MrYXKN6-DD26N7pczbsey1IcLByCHkX6_XByyj5KGq9yeGxLFylcLw4UgCKdA2g_R4aOa7xyg_HsS-oxG1Hbzetn5Ozo64_D4zLnVyg94LQlGIiQ0ddWsmAs19p4a6sAJ4KOyEvPuNdRzYQKVS1UFSoWDmrjD5pasci8Es_JTtu18QWhVsPMqzYNMwBxlGW1nflG18KAsFVgoSBs86Kdz-TjmAPjp0uTEKPcWjgOhOOScNxNQT5s2yzW1Bu31v6M8tvWRNrsdKLrz122Que1Ed4bFoM9kE3wsNdhBtfigJLVjBXkPUrfoXHD4_k6_6MAnUSaLDdRQuBSpuQF2RvVBKP04-KN_rjsFAb3R4UL8nZbjC0x0K2N3SrVgQ1heUH0SO9GPRuXtJcXiRgc0KHUgr-8_eavyEOebACpyffIzrJfxdeArJbNm2Q-vwFAziLw
  priority: 102
  providerName: ProQuest
Title Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma
URI https://www.proquest.com/docview/2435310676
https://www.proquest.com/docview/2432431397
https://pubmed.ncbi.nlm.nih.gov/PMC7414732
https://doaj.org/article/c783cc81ed904bdc9047df12929166f1
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swEBf9YGMvZes25rULHgz2MNxFlqyPhzHSrqUMEkZZIG_ClpS20NiZk0DSv353ipPNWxkDY4wkC8t3J_3kO_-OkHecO82tTZM012nCC9izForrRDqZwdRQ-CyQJPUH4nLIv46y0Q7ZpDtqXuDswa0d5pMa1ncnyx-rz2Dwn4LBK_FxBmsWR28khlilTCT3u2QfViaJGQ36_JdXAZQzeJm5FAnPtNr8RPNgH62FKvD5_z1r_xlJ-dvSdPGUHDSYMu6tleAZ2fHlIXm0zjK5OiSP-43__DlZfrmd1YswS8TVOJ4tpr5OfHmDoq8TV-PUF88Xk6rGuhAjC5egYz6-OusN6AmP_bIJnS3jaQjl87MYQGQ8AUB_jewdK-y5wFj3eWwxU1FZTfIXZHhx_v3sMmlyLyQWMNwcjIdxb3PNqVM6lVJZrTMHBU565KynqZVejJlwWc5E5jLqurmy3SIX1FMr2EuyV1alf0ViLWFXlquCKoA_QtNcj20hc6ZAEYSjLiJ086KNbYjJMT_GnQkbFCXMWjgGhGOCcMx9RD5s75muaTn-2foU5bdtiZTaoaCqr01jocZKxaxV1Dvd5YWzcJZuDH2lgKDFmEbkPUrfoCrC49m8-X8BBokUWqYnGEM3J08jctxqCQZr29Ub_TEbfTcpwFaGdH4iIm-31XgnBsGVvlqENnAgZI-IbOlda2TtmvL2JpCGA3LkkqWv_3sUR-RJGswBGcyPyd68Xvg3AMDmRYfsypHskP3T88G3q074jNEJlvYTCmov1Q
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEJcXBANEYICRQDygsNpx7OQBobIxdWztA9qkvpnEdrdJNClJK9b9KH4j57hJISDtbVIURbHjXM49Pv4OIa-FsKkwhoc8S3kocohZ80SkobIqBtWQu9iDJA1HcnAivozj8Qb51a6FwbTKVid6RW1Lg__IdzjY9QjxzuTH2Y8Qq0bh7GpbQmPFFodu-RNCtvrDwR7Q9w3n-5-PdwdhU1UgNOCdzIEtIuFMlgpmk5QrlZg0jS2csMohGjvjRjk5iaSNs0jGNma2lyWml2eSOWZkBOPeIDfB8PYw2FPjdYDHgPlFuzAnkTs12FKBs6SY-sUjGV52jJ-vEfC_Jfg3O_Mvc7d_n9xr_FTaXzHWA7Lhii1ya1W5crlFbg-bOfmH5GLvvK4WXvPQckLrxcxVoSvOkJ2q0FaoTul8MS0rbPN5t3AIfOvo193-iL0X1F006bgFnfn0QFdTcEzpFIKEU0QEWeLIOebPz6nB6kdFOc0ekZNr-fKPyWZRFu4JoamCSC9LcpaASyVTlqUTk6ssSoC5pGU2IKz90No0YOdYc-O79kFPIvWKOBqIoz1x9GVA3q2vma2gPq7s_Qnpt-6JMN3-RFmd6kbqtVFJZEzCnE17IrcG9spOYCwOXrmcsIC8ReprVCbweCZr1kTASyIsl-7LKMKpU8EDst3pCUrAdJtb_tGNEqr1H5EJyKt1M16JiXWFKxe-D2wYBgREdfiu82bdluL8zAORgzcqVMSfXn3zl-TO4Hh4pI8ORofPyF3u5QFh0bfJ5rxauOfg1c3zF16UKPl23bL7G9sOXz8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Disruption+of+super-enhancer-driven+tumor+suppressor+gene+RCAN1.4+expression+promotes+the+malignancy+of+breast+carcinoma&rft.jtitle=Molecular+cancer&rft.au=Deng%2C+Rong&rft.au=Huang%2C+Jun-Hao&rft.au=Wang%2C+Yan&rft.au=Zhou%2C+Li-Huan&rft.date=2020-08-08&rft.pub=BioMed+Central+Ltd&rft.issn=1476-4598&rft.eissn=1476-4598&rft.volume=19&rft.issue=1&rft_id=info:doi/10.1186%2Fs12943-020-01236-z&rft.externalDocID=A633076042
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon